BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zipfel PF, Wiech T, Rudnick R, Afonso S, Person F, Skerka C. Complement Inhibitors in Clinical Trials for Glomerular Diseases. Front Immunol 2019;10:2166. [PMID: 31611870 DOI: 10.3389/fimmu.2019.02166] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 McElrath TF, Cantonwine DE, Gray KJ, Mirzakhani H, Doss RC, Khaja N, Khalid M, Page G, Brohman B, Zhang Z, Sarracino D, Rosenblatt KP. Late first trimester circulating microparticle proteins predict the risk of preeclampsia < 35 weeks and suggest phenotypic differences among affected cases. Sci Rep 2020;10:17353. [PMID: 33087742 DOI: 10.1038/s41598-020-74078-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Damman J, Mooyaart AL, Bosch TPVD, Seelen MA, Doorn MBV. Lectin and alternative complement pathway activation in cutaneous manifestations of IgA-vasculitis: A new target for therapy? Molecular Immunology 2022;143:114-21. [DOI: 10.1016/j.molimm.2022.01.011] [Reference Citation Analysis]
3 Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet 2021;398:786-802. [PMID: 34175022 DOI: 10.1016/S0140-6736(21)00519-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
4 Poppelaars F, Thurman JM. Complement-mediated kidney diseases. Molecular Immunology 2020;128:175-87. [DOI: 10.1016/j.molimm.2020.10.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Campeau A, Mills RH, Stevens T, Rossitto LA, Meehan M, Dorrestein P, Daly R, Nguyen TT, Gonzalez DJ, Jeste DV, Hook V. Multi-omics of human plasma reveals molecular features of dysregulated inflammation and accelerated aging in schizophrenia. Mol Psychiatry 2021. [PMID: 34741130 DOI: 10.1038/s41380-021-01339-z] [Reference Citation Analysis]
6 Brglez V, Boyer-Suavet S, Seitz-Polski B. Complement Pathways in Membranous Nephropathy: Complex and Multifactorial. Kidney Int Rep 2020;5:572-4. [PMID: 32406418 DOI: 10.1016/j.ekir.2020.02.1033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
7 Komeno M, Pang X, Shimizu A, Molla MR, Yasuda-Yamahara M, Kume S, Rahman NIA, Soh JEC, Nguyen LKC, Ahmat Amin MKB, Kokami N, Sato A, Asano Y, Maegawa H, Ogita H. Cardio- and reno-protective effects of dipeptidyl peptidase III in diabetic mice. J Biol Chem 2021;296:100761. [PMID: 33971198 DOI: 10.1016/j.jbc.2021.100761] [Reference Citation Analysis]
8 Barratt J, Weitz I. Complement Factor D as a Strategic Target for Regulating the Alternative Complement Pathway. Front Immunol 2021;12:712572. [PMID: 34566967 DOI: 10.3389/fimmu.2021.712572] [Reference Citation Analysis]
9 Tang SCW, Yiu WH. Innate immunity in diabetic kidney disease. Nat Rev Nephrol 2020;16:206-22. [PMID: 31942046 DOI: 10.1038/s41581-019-0234-4] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 20.5] [Reference Citation Analysis]
10 Youssef L, Miranda J, Blasco M, Paules C, Crovetto F, Palomo M, Torramade-Moix S, García-Calderó H, Tura-Ceide O, Dantas AP, Hernandez-Gea V, Herrero P, Canela N, Campistol JM, Garcia-Pagan JC, Diaz-Ricart M, Gratacos E, Crispi F. Complement and coagulation cascades activation is the main pathophysiological pathway in early-onset severe preeclampsia revealed by maternal proteomics. Sci Rep 2021;11:3048. [PMID: 33542402 DOI: 10.1038/s41598-021-82733-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 de Cos M, Xipell M, García-Herrera A, Lledo GM, Guillen E, Blasco M, Espinosa G, Cervera R, Quintana LF. Assessing and counteracting fibrosis is a cornerstone of the treatment of CKD secondary to systemic and renal limited autoimmune disorders. Autoimmun Rev 2021;21:103014. [PMID: 34896651 DOI: 10.1016/j.autrev.2021.103014] [Reference Citation Analysis]
12 Anderson JG, Hennet P. Management of Severe Oral Inflammatory Conditions in Dogs and Cats. Vet Clin North Am Small Anim Pract 2022;52:159-84. [PMID: 34838249 DOI: 10.1016/j.cvsm.2021.09.008] [Reference Citation Analysis]
13 Vandendriessche S, Cambier S, Proost P, Marques PE. Complement Receptors and Their Role in Leukocyte Recruitment and Phagocytosis. Front Cell Dev Biol 2021;9:624025. [PMID: 33644062 DOI: 10.3389/fcell.2021.624025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
14 Ruiz-Molina N, Parsons J, Müller M, Hoernstein SNW, Bohlender LL, Pumple S, Zipfel PF, Häffner K, Reski R, Decker EL. A synthetic protein as efficient multitarget regulator against complement over-activation. Commun Biol 2022;5:152. [PMID: 35194132 DOI: 10.1038/s42003-022-03094-5] [Reference Citation Analysis]
15 Genest DS, Bonnefoy A, Khalili M, Merlen C, Genest G, Lapeyraque A, Patey N, Smail N, Royal V, Troyanov S. Comparison of Complement Pathway Activation in Autoimmune Glomerulonephritis. Kidney International Reports 2022. [DOI: 10.1016/j.ekir.2022.02.002] [Reference Citation Analysis]
16 Milosevits G, Mészáros T, Őrfi E, Bakos T, Garami M, Kovács G, Dézsi L, Hamar P, Győrffy B, Szabó A, Szénási G, Szebeni J. Complement-mediated hypersensitivity reactions to an amphotericin B-containing lipid complex (Abelcet) in pediatric patients and anesthetized rats: Benefits of slow infusion. Nanomedicine 2021;34:102366. [PMID: 33549818 DOI: 10.1016/j.nano.2021.102366] [Reference Citation Analysis]
17 Koopman JJE, van Essen MF, Rennke HG, de Vries APJ, van Kooten C. Deposition of the Membrane Attack Complex in Healthy and Diseased Human Kidneys. Front Immunol 2020;11:599974. [PMID: 33643288 DOI: 10.3389/fimmu.2020.599974] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Al-otaibi JS, Mary YS, Mary YS. Theoretical Insights into the Solvation, Electronic, Chemical Properties and Molecular Docking of Some Thiazole Derivatives. Polycyclic Aromatic Compounds. [DOI: 10.1080/10406638.2022.2030767] [Reference Citation Analysis]
19 Vivarelli M, van de Kar N, Labbadia R, Diomedi-Camassei F, Thurman JM. A clinical approach to children with C3 glomerulopathy. Pediatr Nephrol 2021. [PMID: 34002292 DOI: 10.1007/s00467-021-05088-7] [Reference Citation Analysis]
20 Seikrit C, Rauen T, Stamellou E, Floege J. Precision medicine in immunoglobulin A nephropathy: still a journey ahead. Nephrol Dial Transplant 2021;36:24-30. [PMID: 34153983 DOI: 10.1093/ndt/gfab032] [Reference Citation Analysis]
21 Fernandez-Ruiz R, Blank RB, Wu M, Belmont HM. C3 glomerulonephritis and systemic lupus erythematosus: A report of a patient treated with eculizumab and review of the literature. Lupus 2021;:9612033211027938. [PMID: 34192954 DOI: 10.1177/09612033211027938] [Reference Citation Analysis]
22 Hamilton P, Kanigicherla D, Hanumapura P, Blaikie K, Ritchie J, Sinha S, Brenchley P, Mitra S. Peptide GAM immunoadsorption in anti-PLA2 R positive autoimmune membranous nephropathy. The PRISM trial. J Clin Apher 2021. [PMID: 34753218 DOI: 10.1002/jca.21949] [Reference Citation Analysis]
23 Khalili M, Bonnefoy A, Genest DS, Quadri J, Rioux JP, Troyanov S. Clinical Use of Complement, Inflammation, and Fibrosis Biomarkers in Autoimmune Glomerulonephritis. Kidney Int Rep 2020;5:1690-9. [PMID: 33102961 DOI: 10.1016/j.ekir.2020.07.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Demir F, Troldborg A, Thiel S, Lassé M, Huesgen PF, Tomas NM, Wiech T, Rinschen MM. Proteolysis and inflammation of the kidney glomerulus. Cell Tissue Res 2021. [PMID: 33864499 DOI: 10.1007/s00441-021-03433-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Zipfel PF, Wiech T, Stea ED, Skerka C. CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. J Am Soc Nephrol 2020;31:241-56. [PMID: 31980588 DOI: 10.1681/ASN.2019050515] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
26 Portilla D, Xavier S. Role of intracellular complement activation in kidney fibrosis. Br J Pharmacol 2021;178:2880-91. [PMID: 33555070 DOI: 10.1111/bph.15408] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
27 Zhang T, Feng X, Dong J, Xu Z, Feng B, Haas KM, Cawthon PM, Beavers KM, Nicklas B, Kritchevsky S. Cardiac troponin T and autoimmunity in skeletal muscle aging. Geroscience 2022. [PMID: 35034279 DOI: 10.1007/s11357-022-00513-7] [Reference Citation Analysis]
28 Faria B, Canão P, Cai Q, Henriques C, Matos AC, Poppelaars F, Gaya da Costa M, Daha MR, Silva R, Pestana M, Seelen MA. Arteriolar C4d in IgA Nephropathy: A Cohort Study. Am J Kidney Dis 2020;76:669-78. [PMID: 32439421 DOI: 10.1053/j.ajkd.2020.03.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
29 Ram Kumar Pandian S, Arunachalam S, Deepak V, Kunjiappan S, Sundar K. Targeting complement cascade: an alternative strategy for COVID-19. 3 Biotech 2020;10:479. [PMID: 33088671 DOI: 10.1007/s13205-020-02464-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
30 Reinhard L, Stahl RAK, Hoxha E. Is primary membranous nephropathy a complement mediated disease? Mol Immunol 2020;128:195-204. [PMID: 33142137 DOI: 10.1016/j.molimm.2020.10.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
31 Ort M, Dingemanse J, van den Anker J, Kaufmann P. Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway. Front Immunol 2020;11:599417. [PMID: 33362783 DOI: 10.3389/fimmu.2020.599417] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Chiu YL, Lin WC, Shu KH, Fang YW, Chang FC, Chou YH, Wu CF, Chiang WC, Lin SL, Chen YM, Wu MS. Alternative Complement Pathway Is Activated and Associated with Galactose-Deficient IgA1 Antibody in IgA Nephropathy Patients. Front Immunol 2021;12:638309. [PMID: 34177889 DOI: 10.3389/fimmu.2021.638309] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
33 Wan S, Wan S, Jiao X, Cao H, Gu Y, Yan L, Zheng Y, Niu P, Shao F. Advances in understanding the innate immune-associated diabetic kidney disease. FASEB J 2021;35:e21367. [PMID: 33508160 DOI: 10.1096/fj.202002334R] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Tille A, Lehnert T, Zipfel PF, Figge MT. Quantification of Factor H Mediated Self vs. Non-self Discrimination by Mathematical Modeling. Front Immunol 2020;11:1911. [PMID: 33013842 DOI: 10.3389/fimmu.2020.01911] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Sethi S, De Vriese AS, Fervenza FC. Acute glomerulonephritis. The Lancet 2022;399:1646-63. [DOI: 10.1016/s0140-6736(22)00461-5] [Reference Citation Analysis]
36 Bickel JK, Voisin TB, Tate EW, Bubeck D. How Structures of Complement Complexes Guide Therapeutic Design. Subcell Biochem 2021;96:273-95. [PMID: 33252733 DOI: 10.1007/978-3-030-58971-4_7] [Reference Citation Analysis]
37 Carpenter S, Cohen Tervaert JW, Yacyshyn E. Advances in therapeutic treatment options for ANCA-associated vasculitis. Expert Opinion on Orphan Drugs 2020;8:127-36. [DOI: 10.1080/21678707.2020.1760837] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
38 Tinawi M. Update on the etiology, classification, and management of glomerular diseases. Avicenna J Med 2020;10:61-7. [PMID: 32500044 DOI: 10.4103/ajm.ajm_136_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Detsika MG, Lianos EA. Regulation of Complement Activation by Heme Oxygenase-1 (HO-1) in Kidney Injury. Antioxidants (Basel) 2021;10:60. [PMID: 33418934 DOI: 10.3390/antiox10010060] [Reference Citation Analysis]
40 Wendt R, Siwy J, He T, Latosinska A, Wiech T, Zipfel PF, Tserga A, Vlahou A, Rupprecht H, Catanese L, Mischak H, Beige J. Molecular Mapping of Urinary Complement Peptides in Kidney Diseases. Proteomes 2021;9:49. [DOI: 10.3390/proteomes9040049] [Reference Citation Analysis]
41 Hu Y, Chi L, Kuebler WM, Goldenberg NM. Perivascular Inflammation in Pulmonary Arterial Hypertension. Cells 2020;9:E2338. [PMID: 33105588 DOI: 10.3390/cells9112338] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]